Pacira BioSciences, Inc.

NasdaqGS:PCRX 株式レポート

時価総額：US$984.2m

Pacira BioSciences 配当と自社株買い

配当金 基準チェック /06

Pacira BioSciences配当金を支払った記録がありません。

主要情報

n/a

配当利回り

15.6%

バイバック利回り

総株主利回り15.6%
将来の配当利回りn/a
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Seeking Alpha • Aug 08

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Summary Pacira BioSciences is evolving from a single-product specialty pharma into a self-funded musculoskeletal pain platform with expanding pipeline optionality. EXPAREL's separate reimbursement, particularly via the NOPAIN Act and UnitedHealthcare, shifts economics and broadens institutional access, supporting recurring protocol-based utilization. The iovera° divestiture strengthens PCRX’s balance sheet, funds higher-value pharmaceutical programs, and preserves upside through milestone payments. PCRX trades at a steep valuation discount, despite positive EBITDA, falling share count, late-stage catalysts, and underappreciated pipeline and reimbursement-driven growth. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 25

PCRX: Real World Procedure Mix And Proxy Battle Will Shape Repricing

Analysts have nudged their price target on Pacira BioSciences higher by $2, citing updated assumptions around revenue growth, profit margins, and future P/E that reflect recent real world data and evolving views on the company’s procedure mix. Analyst Commentary Bullish analysts covering Pacira BioSciences are leaning into new real world data and refreshed assumptions, using these inputs to fine tune their models rather than overhaul them.
ナラティブ更新 • Jun 03

PCRX: Real World Outcomes And Activist Pressure Will Drive Future Repricing

Analysts have kept Pacira BioSciences' fair value estimate steady at $38.00 while adjusting underlying assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a mix of recent price target moves and updated views on the company’s data and outlook.
ナラティブ更新 • May 01

PCRX: Real World Procedure Data Will Support Future Upside Repricing

Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
ナラティブ更新 • Apr 16

PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook

Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.
ナラティブ更新 • Apr 01

PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside

Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.
ナラティブ更新 • Mar 17

PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside

Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).
ナラティブ更新 • Mar 03

PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure

Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.
ナラティブ更新 • Feb 17

PCRX: Asia Partnership Will Drive Future Upside Potential

Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.
ナラティブ更新 • Feb 02

PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential

Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).
ナラティブ更新 • Jan 19

PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential

Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.
分析記事 • Jan 17

Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive

Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...
ナラティブ更新 • Jan 05

PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential

Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.
ナラティブ更新 • Dec 14

PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential

Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).
分析記事 • Nov 13

Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality

When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
ナラティブ更新 • Aug 17

Policy Changes And Partnerships Will Expand Ambulatory Market Reach

The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.
分析記事 • Jun 11

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Apr 09

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking Alpha
分析記事 • Apr 07

Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough

You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...
Seeking Alpha • Mar 14

Pacira BioSciences: Back On An Uptrend After Positive Developments

Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking Alpha
分析記事 • Jan 30

Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jan 03

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...
Seeking Alpha • Nov 25

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha

決済の安定と成長

配当データの取得

安定した配当: PCRXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: PCRXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Pacira BioSciences 配当利回り対市場
PCRX 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (PCRX)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Pharmaceuticals)1.8%
アナリスト予想 (PCRX) (最長3年)n/a

注目すべき配当: PCRXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: PCRXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: PCRXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: PCRXが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/21 16:39
終値2026/09/21 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Pacira BioSciences, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31

アナリスト機関
Jenna DavidnerBarclays
Anita DushyanthBerenberg
Gary NachmanBMO Capital Markets Equity Research